Project Grant K23HL173636
- Federal Project Grant Award Summary Massachusetts General Hospital's Research Management Division received a $867,656 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on May 1, 2026, with a completion date of February 28, 2031. The award funds research to determine the effectiveness of guideline-directed medical therapies (GDMT) for heart failure with mildly reduced ejection fraction (HFmrEF)—a...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded $614,843 to Massachusetts General Hospital's Research Management Division for a five-year investigation beginning May 1, 2026 and concluding February 28, 2031. The funded research examines the relationship between indexed exercise blood pressure (systolic blood pressure normalized to oxygen consumption, or SBP/VO2) and adverse vascular...
- Federal Grant Award Summary Dr. Cross's K01 career development grant, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), totaling $142,870 and spanning September 1, 2025, through August 31, 2029, supports a mixed-methods research initiative examining end-of-life care disparities for adults with heart failure. The project addresses a critical gap in Medicare hospice policy, which was designed for cancer patients and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1.28M to the University of Massachusetts Medical School for research investigating the role of thromboxane A₂ (TXA₂) as a biomarker and mediator of heart failure risk. Under the Cardiovascular Diseases Research program (CFDA 93.837), this award, effective July 15, 2026, through March 31, 2030, funds a multi-site investigation measuring urinary thromboxane B₂ metabolites indexed to...
- This $2,497,615 federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to evaluate the impact of new Medicare home health agency (HHA) payment policies on healthcare utilization and outcomes for Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD). The project has three key objectives: 1) characterizing changes in the ADRD beneficiary population eligible for HHA services, 2) evaluating the effect of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant totaling $248,999 (awarded July 5, 2026; completion date June 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms underlying heart failure with preserved ejection fraction (HFpEF). The research will examine how reduced hypusination of eukaryotic translation initiation factor 5A (EIF5A) impairs the...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a five-year Project Grant of $780,960 to Kaiser Foundation Hospitals (Kaiser Permanente), effective July 3, 2026 through June 30, 2031. The award funds a randomized controlled trial designed to evaluate and improve treatment adherence among young adults (ages 18–25) with obstructive sleep apnea (OSA). The research will test two...
- This $1.49M Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research investigating combination therapy using hydrogen sulfide (H2S) donors and glucagon-like peptide-1 (GLP-1) agonists to treat heart failure with preserved ejection fraction (HFpEF). The research, conducted by Cedars-Sinai Medical Center in West Hollywood, California, and scheduled for completion by May 31, 2029, will deliver...
- Federal Grant Award Summary Brigham and Women's Hospital received an award of $855,585 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of August 20, 2025, and a completion date of July 31, 2028. This Project Grant funds the development and adaptation of an antihypertensive self-titration intervention for routine implementation in U.S. primary care settings. The project addresses the clinical challenge...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant to Brigham & Women's Hospital on September 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Optimizing Cardiovascular Care and Promoting Excellent Health Outcomes for Adults with Diabetes Across Settings," will develop and validate the PREDICT-DM Global Simulation Model to assess the clinical impact, cost-effectiveness,...
EVALUATING POLICIES TO IMPROVE HEART FAILURE OUTCOMES IN MEDICARE - PROJECT SUMMARY/ABSTRACT IN THE UNITED STATES, 6.5 MILLION PEOPLE HAVE HEART FAILURE (HF), THE VAST MAJORITY OF WHOM ARE ENROLLED IN MEDICARE. UNFORTUNATELY, HF MORTALITY IS RISING AMONG MEDICARE BENEFICIARIES DESPITE SIGNIFICANT ADVANCES IN HF THERAPIES, AND EVIDENCE SUGGESTS THIS MAY BE PARTIALLY DUE TO GAPS IN HEALTH CARE ACCESS AND AFFORDABILITY. HOWEVER, RECENT MEDICARE POLICY CHANGES COULD MEANINGFULLY ADDRESS THESE GAPS, AND ULTIMATELY IMPROVE HF OUTCOMES NATIONWIDE. ONE MAJOR CHANGE IN THE MEDICARE PROGRAM HAS BEEN THE RAPID GROWTH OF MEDICARE ADVANTAGE (MA) PLANS, WHICH NOW COVER OVER 50% OF ALL BENEFICIARIES, AND MAY BE AN IMPORTANT STRATEGY TO IMPROVE HF CARE. IN CONTRAST TO FEE-FOR-SERVICE (FFS) MEDICARE, THESE PRIVATE INSURANCE PLANS RECEIVE CAPITATED PAYMENTS FROM THE GOVERNMENT, AND THEIR DESIGN COULD IMPACT HF PATIENTS IN BOTH BENEFICIAL AND HARMFUL WAYS. IN AIM 1, WE WILL DETERMINE WHETHER HEALTH CARE ACCESS, AFFORDABILITY, AND CLINICAL OUTCOMES DIFFER AMONG MEDICARE BENEFICIARIES WITH HF ENROLLED IN MA VS FFS MEDICARE, WHICH IS ESPECIALLY IMPORTANT GIVEN THE SUBSTANTIAL BURDEN OF HF IN MEDICARE. IN ADDITION TO THE RAPID GROWTH IN MA, THE RECENT PASSAGE OF THE INFLATION REDUCTION ACT (IRA) HAS THE POTENTIAL TO IMPROVE HF OUTCOMES IN MEDICARE. THE IRA WILL CAP ANNUAL OOP DRUG COSTS AT $2000/YEAR AND EXPAND LOW-INCOME SUBSIDIES FOR MEDICARE BENEFICIARIES, WHICH COULD HAVE MAJOR IMPLICATIONS FOR THOSE WITH HF. IN AIM 2, WE WILL USE QUASI-EXPERIMENTAL APPROACHES TO DETERMINE WHETHER THE IRA LEADS TO REAL-WORLD CHANGES IN OOP COSTS AND ASSOCIATED IMPROVEMENTS IN MEDICATION ADHERENCE AND OUTCOMES FOR MEDICARE BENEFICIARIES WITH HF. DATA ON THE REAL-WORLD IMPACT OF THE IRA WILL BE CRITICAL AS POLICYMAKERS CONSIDER STRATEGIES TO IMPROVE HF OUTCOMES IN MEDICARE. FINALLY, AS ENROLLMENT IN MA CONTINUES AND THE IRA IS FULLY IMPLEMENTED, IDENTIFYING ONGOING AND/OR NEW BARRIERS TO HF CARE IN MEDICARE WILL BE CRITICAL. IN AIM 3, WE WILL USE SEMI-STRUCTURED INTERVIEWS OF MEDICARE BENEFICIARIES WITH HF AND CLINICIANS TO IDENTIFY BARRIERS IN CARE ACCESS, AFFORDABILITY, AND GDMT ADHERENCE, AND NOVEL STRATEGIES TO ADDRESS THEM. QUALITATIVE RESULTS FROM THESE INTERVIEWS WILL SERVE AS PRELIMINARY DATA FOR FUTURE STUDIES THAT TEST AND IMPLEMENT NEW INTERVENTIONS TO IMPROVE HF OUTCOMES IN MEDICARE. THE OVERARCHING GOAL OF THIS PROPOSAL IS TO USE MEDICARE CLAIMS, NATIONAL SURVEY, AND QUALITATIVE DATA COMBINED WITH ADVANCED STATISTICAL METHODS TO EVALUATE THE IMPACT OF NEW MEDICARE POLICIES ON THE MILLIONS OF BENEFICIARIES WITH HF, AND TO IDENTIFY EMERGING BARRIERS TO CARE IN THIS POPULATION. I WILL PERFORM THIS WORK IN THE SETTING OF A COMPREHENSIVE CAREER DEVELOPMENT PLAN DESIGNED TO PROVIDE ME WITH THE EXPERIENCE AND SKILLS NECESSARY TO BECOME AN INDEPENDENT RESEARCH SCIENTIST. MY LONG-TERM CAREER GOAL IS TO USE MIXED METHODS TO EVALUATE HOW POLICIES AND INTERVENTIONS IMPACT CARE DELIVERY AND OUTCOMES FOR HF PATIENTS, AND I WILL USE THE RESEARCH AND SKILLS FROM THIS K23 AS A SPRINGBOARD FOR AN R01.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/30/26 | ||
| Not listed | $169.2k | 7/4/25 | ||
| Not listed | $169.4k | 6/28/24 |